MEDSTREAM PROGRAMMABLE INFUSION PUMP SYSTEM
Intera Oncology · Decision date Mar 16, 2026
What did the FDA decide?
FDA records P890055/S093 as a supplement to PMA P890055, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 16, 2026.
FDA approval order statement
a change of the secondary supplier to conduct receiving/inspection and packaging/labeling activities for a component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General Hospital
- Decision date
- Mar 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P890055/S093
- Regulatory pathway
- PMA supplement
- Applicant
- Intera Oncology
- Product code
- LKK
- Decision code
- OK30
- Decision date
- Mar 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pump, infusion, implanted, programmable.
- Applicant
- Intera Oncology
- Product code
- LKK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P890055/S093 received
Application receipt date recorded by FDA.
P890055/S092 · Related supplement
lntera 3000 Hepatic Artery Infusion Pump
P890055/S093 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P890055. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P890055
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
lntera 3000 Hepatic Artery Infusion PumpP890055/S092 | Intera Oncology | PMA supplement | Feb 26, 2026 | FDA |
Explore the linked device profile
Other records with product code LKK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 27, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
SynchroMed III Pump Drug Delivery Infusion PumpP860004/S461 | Medtronic, Inc. | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Intera Oncology
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 180 Wells Ave., Suite 300a, Newton, MA, 02459
Sources and methodology
- Original FDA record: P890055/S093
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

